Podcasts about life sciences

Rebecca Bloom is a former employee benefits and executive compensation attorney who spent more than 25 years helping women navigate cancer, work, insurance, disability coverage, and financial survival. She is the founder and author of When Women Get Sick, a book built from decades inside the legal, workplace, and patient advocacy systems most people only discover after diagnosis.Bloom started in Big Law at Simpson Thacher handling employee benefits and compensation work she originally chose to pay off student loans. Then her mother was diagnosed with breast cancer. Suddenly the language she used in corporate law offices became the language of survival at home. Explanation of benefits forms. Coverage disputes. Second opinions. Disability protections. Medical leave. Bills no one could explain.That collision changed the direction of her life.In this episode, Bloom explains how serious illness quietly turns patients into unpaid administrators managing paperwork, logistics, financial risk, and emotional labor while trying to survive treatment. She breaks down how employer based health insurance shapes nearly every aspect of cancer care in America and why women often carry the invisible burden of protecting everyone else from discomfort while they themselves fall apart.The conversation digs into workplace power, the illusion of the healthcare “safety net,” caregiver exhaustion, and the class divide hiding underneath patient empowerment culture. Bloom explains why educated, insured women with resources still struggle to navigate healthcare bureaucracy and what happens to patients without those advantages.This episode explores cancer care, health insurance, employee benefits, patient advocacy, workplace protections, caregiving, and the structural incentives that force sick people to become project managers of their own survival.RELATED LINKSRebecca BloomWhen Women Get SickBay Area Cancer ConnectionsSimpson Thacher & BartlettFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Vasanta Pundarika built her career inside healthcare investment banking before launching Lotuspring, an advisory firm focused on women's health and behavioral health. She spent nearly 20 years advising healthcare systems, treatment providers, and growth stage companies on mergers, financing, and operational strategy while watching the industry repeatedly misunderstand the people it claimed to serve.The conversation starts unexpectedly with anthropology, bread, and language. Vasanta explains how she spent years changing the pronunciation of her own name to make other people comfortable before eventually reclaiming it. That thread opens into a much larger discussion about adaptation, identity, and what institutions quietly train people to tolerate.From there, the discussion moves into behavioral health, women delaying care, and the invisible labor that healthcare business models routinely ignore. During COVID, Vasanta noticed men's behavioral health units refilled faster than women's units. The reason had nothing to do with demand. Women were still home managing caregiving responsibilities, children, aging parents, and households while their own mental health collapsed in the background.The episode examines what happens when healthcare companies become “snazzy big brands” before building real clinical substance underneath. Vasanta describes the tension between mission and margin inside healthcare startups, private equity backed care models, and behavioral health expansion. The conversation pushes on who benefits when healthcare scales aggressively, who absorbs the operational pressure, and how patient trust erodes long before executives notice it on a dashboard.They also discuss patient advocacy culture, anthropology as systems analysis, healthcare capitalism, prior authorization, investor language, and why some clinically excellent companies never survive long enough to scale.RELATED LINKSVasanta PundarikaLotuspringWomen's Health HorizonsSakhi for South Asian SurvivorsNACDPrinceton University Anthropology DepartmentFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The latest episode of the Cambridge Tech Podcast features a fascinating panel discussion on international trade recorded live at this year's Cambridge Wide Open Week.Steven Lynch, Director of International Trade at the British Chambers of Commerce (BCC), opens with a sobering statistic: whilst only 10% of British businesses export, the BCC's network achieves a remarkable 45%. This disparity represents a significant untapped opportunity. As Lynch points out, "If we increased UK exports by 2%, we could improve UK GDP by 0.6%."The problem isn't a lack of innovation or ambition; it's a delivery gap. UK founders and scientists often lack the business expertise and market clarity needed to confidently enter international markets. This is where the new trade accelerator comes in.Rather than offering generic webinars about exporting, the BCC has created something fundamentally different: an end-to-end, process-driven accelerator specifically targeting life sciences companies interested in Singapore.Singapore might not be the obvious first choice for UK startups - the US typically dominates - but it's positioned as a strategic gateway to Southeast Asia. With a population of 6 million, Singapore punches well above its weight as a hub for healthcare innovation and life sciences.Jay Sadanandan, a Singapore life sciences expert, highlights the market's unique advantages:The Health Sciences Authority recently launched a close collaboration with the UK's MHRA, enabling regulatory expediency for innovative technologiesAccess to world-class clinical research infrastructure and patient populationsSingapore's ambitious government vision to solve prevention through treatment across healthcareThe 10 selected companies span pre-seed to Series C stages and focus on areas where UK strength aligns with Singapore opportunity: genomics, molecular diagnostics, advanced therapeutics, and enabling technologies like biologic stabilisation. Importantly, companies aren't required to relocate or abandon UK operations. Instead, they use Singapore as a commercial testbed, a lower-risk environment to validate their business model before scaling across Asia Pacific, the US, or beyond.What's Next?The pilot launches in September 2026, but the ambitions extend far beyond Singapore. Lynch reveals plans to scale to Hong Kong, the Gulf, and other strategic markets. The ultimate goal? Moving from 15 businesses entering one market annually to 15 businesses entering different markets each month.For UK startup founders and investors watching the export opportunity, this episode offers genuine insight into how the next generation of British life sciences companies might achieve global scale, and why Singapore might be the launchpad you haven't considered yet.Listen to the full episode on the Cambridge Tech Podcast to hear the complete discussion, including audience Q&A and practical advice for companies considering international expansion.Headline sponsor Holden Polestar Produced by Cambridge TV #CamTechPod Hosted on Acast. See acast.com/privacy for more information.

“The future of biology is programmable.”To give you a sense of how important this topic is, Patrick Hsu is the first guest we've had back to Ground Truths since the podcast began a few years ago. Nearly 2 years ago we spoke about digital biology but so much has happened since to help unravel the complexities in the language of life. Patrick is a co-founder and core investigator at the Arc Institute. His work is at the intersection of biology, engineering, and AI. At the ripe old age of 33, he's a pioneer of genome editing technologies and my go-to for tracking progress in digital biology. Besides that he's a great explainer with frequent use of metaphors and simplification of very complicated stuff.Here's what we discussed with the relevant links:—Our recent review in Nature Biotechnology on the large language of life models (LLLMs). GBAI-generalist biological artificial intelligence —The 2 multi-agent AI Nature papers in May for accelerating drug discovery: Full House (Robin) and Google Deep Mind (Co-Scientist) Multiple drug candidates were described as an outgrowth of multi-agent AI , with a 200-fold decrease in workflow time.Below Figure from synthesis of the Robin and Co-Scientist papers: “AI devises hypotheses and ways to test them,” Nature News and Views, by Oliver Elemento—Biomni published in Science 9 JulyAn infographic by NotebookLM below helps give you a sense of what—a diversity of important tasks— accomplished by Biomni—New workbench offerings by the AI companies including Anthropic's Claude Science, Open AI, Google DeepMind and the competition with academic spinoffs—Spud Cells —Virtual Cell project, which it's such a big deal, and the importance of perturbations—Alzheimer's disease with OpenAI for finding mechanistic new targets for drug discovery—The Nature Editorial —Mid-Journey's Ultrasound Imaging of the “Whole-Body” (and we're not imaginative enough, the need to think big)—Mitigating the worries about humans as lab assistants and nefarious use to produce bioweapons *******************************************************************************A big thanks to Ground Truths subscribers from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you're not a subscriber, please join!If you found this interesting PLEASE share it!Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support a record number of 61 summer interns here with us now! These are high school, college and medical students selected from thousands of applicants. We couldn't do this expanded program without the funds coming in through Ground Truths.Finally, thank you Alan Heldman MD, Bob Fleischman, Jeanie, Maureen Susannah, Mary Powers, and more than 400 others for tuning into my live video with Patrick Hsu! Join me for my next live video in the app. Get full access to Ground Truths at erictopol.substack.com/subscribe

As pharmaceutical manufacturers work to reduce energy consumption and meet sustainability targets, attention is expanding beyond core production processes to the utility systems that support manufacturing. Steam systems, which play a critical role in sterilization, heating, and HVAC operations, can account for a significant share of a facility's energy consumption. Yet things like manual inspection practices and undetected steam trap failures often leave manufacturers with unnecessary energy losses, higher emissions, and increased operating costs. In this episode of Off Script, sponsored by Emerson, we spoke with Tom Belling, global director of Life Sciences at Emerson, about the growing role utilities play in pharmaceutical sustainability strategies, and the significance of steam systems within that. The conversation explores why steam systems have become an important opportunity for improving operational efficiency and how continuous monitoring technologies are helping manufacturers identify failures earlier without disrupting operations. Belling also discusses how wireless sensing, acoustic monitoring, and data-driven maintenance can improve reliability, support sustainability, and reduce maintenance costs while protecting product quality.

Not good news: Bugs are disappearing. Your windshield is way cleaner than it used to be. Hosts Kat and Tiff explore the different factors on why insect decline is happening, along with the (very scary) link between insect decline and food security. Listen to get answers to these questions:Why are insects disappearing? Why do we need insects?What would happen if insects went instinct? What can we do about it?SourcesNPR: https://www.npr.org/2025/09/12/nx-s1-5535551/insect-populations-human-interference-studyFriends of the Mississippi River: https://fmr.org/updates/conservation/why-insects-matter-and-what-you-can-do-about-their-declinePenn State Huck Institute of Life Sciences: https://www.huck.psu.edu/institutes-and-centers/insect-biodiversity-center/why-we-need-insectsOklahoma State Extension: https://extension.okstate.edu/fact-sheets/beneficial-insectsHuck Institute (again): https://www.huck.psu.edu/institutes-and-centers/insect-biodiversity-center/helping-insectsUC IPM: https://ipm.ucanr.edu/bee-precaution-pesticide-ratings/#gsc.tab=0Patreon: patreon.com/greeningupmyactInstagram: @greeningupmyactFacebook: Greening Up My ActEmail us with questions: greeningupmyact@gmail.comYouTube: Greening Up My Act

Sesh looks like a consumer brand. 8VC looks like the last fund that would back it. That mismatch is the fastest way to see what Austin is becoming.Sesh founder Max Cunningham and 8VC's Jake Medwell start with the logic that makes the deal make sense. Sesh holds a legal moat most competitors can't cross for years, and it earns software-like margins on a physical product. From there the conversation opens into a bigger question about where ambitious companies belong, and why more of them are choosing a city that now draws the founders and families betting on that future.Agenda00:00 What Sesh is06:05 Why 8VC backed a nicotine company10:44 Regulatory timing and the six-year door16:37 Software margins and owning the factory22:01 Who buys this and why the market is growing29:27 Why some companies need SF and others do not34:32 What Austin talent looks like now42:10 The Elon spillover and the coming IPO wave 48:37 Raising kids in the AI age55:07 Safety, schools, and what comes nextGuest LinksSesh: Max Cunningham, Website, X, Instagram8VC: Jake Medwell, Website, X -------------------Austin Next Links: Website, X/Twitter, YouTube, LinkedInEcosystem Metacognition Substack

In this episode of Tiny Matters, a listener who works in a pathology lab explains how even the ickiest specimens become ho-hum with time, sending Sam and Deboki down a rabbit hole of pathology history and the bizarre life of Rudolf Virchow, the “father of pathology” who was also rumored to have brought worm-filled sausages to a duel. Then, a listener's sourdough experiments spark a conversation about yeast and how these microscopic organisms are the chemists behind tasty bread, beer, wine, and more.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

After nearly three years of sluggish job growth, hiring is turning a corner in the U.S. life sciences industry, while the talent pool is expanding beyond the sector's traditional hubs. On a special episode of the BioCentury This Week podcast, Ian Anderson, senior director, head of U.S. life sciences & healthcare research at CBRE, joins BioCentury's analysts to discuss the company's recent report on life sciences talent trends, and how those trends are driving property demand. This episode of the BioCentury This Week podcast has been brought to you by CBRE.View full story: https://www.biocentury.com/article/660118#LifeSciences #BiotechJobs #Workforce #LifeSciencesRealEstate #Talent00:01 - Sponsor Message: CBRE00:45 - Industry Inflection Point04:17 - Report Methodology10:08 - Growth Beyond Big Hubs15:28 - Capital Markets Signals18:48 - AI and Space Use20:50 - Emerging Talent26:34 - Up-and-Coming CitiesTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Michel Roger of Accenture joins us to discuss how AI, autonomy, robotics, and data governance are reshaping logistics, workforce skills, and supply chain leadership.Download the ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠episode transcript⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠===== This week, we, together with Michel Roger of Accenture explore the future of logistics, from agentic AI and physical robotics to connected workforce models and real-time digital twins. Come join us to learn how companies can scale AI beyond pilots, reshape warehouse operations, strengthen multi-tier visibility, and prepare talent for a more autonomous, exception-driven supply chain. ===== Guest: Michel Roger, Global SAP Supply Chain Leader, AccentureThroughout his career, Michel has specialized in designing, implementing and deploying SAP solutions for Supply Chain processes for global clients in North America, Latin America and Europe. He has worked mostly for Consumer Goods and Life Sciences clients. Internally to Accenture, he is responsible for developing Supply Chain & Operations capabilities of 5,000+ people specialized around SAP solutions covering planning, distribution, and manufacturing processes. Host 1: Richard Howells⁠⁠⁠⁠⁠⁠⁠Richard Howells⁠⁠⁠⁠⁠⁠⁠ has been working in the Supply Chain Management and Manufacturing space for over 30 years. He is responsible for driving the thought leadership and awareness of SAP's ERP, Finance, and Supply Chain solutions and is an active writer, podcaster, and thought leader on the topics of supply chain, Industry 4.0, digitization, and sustainability.Host 2: Oyku Ilgar, SAP  Oyku Ilgar is a marketer and thought leader specializing in SAP's digital supply chain and ERP solutions since 2017. As a marketer, blogger, and podcaster, she creates engaging content that highlights innovative SAP technologies and explores key topics including business trends, AI, Industry 4.0, and sustainability.   She holds dual bachelor's degrees in Finance & Accounting and English Translation, along with a master's degree in Business Administration and Foreign Trade, specializing in marketing. With her background in digital transformation, Oyku communicates technology trends and industry insights to help professionals navigate the evolving business landscape.  ===== Show Links:AccentureSupply Chain Management:  ⁠⁠⁠SAP Supply Chain Management⁠⁠⁠ ⁠⁠⁠SAP Insights: Supply Chain⁠⁠⁠       Follow Us on Social Media : Michel Roger: LinkedIn Richard Howells: ⁠⁠⁠LinkedIn⁠⁠⁠, Oyku Ilgar: ⁠⁠⁠LinkedIn⁠⁠⁠      SAP Digital Supply Chain: ⁠⁠⁠LinkedIn⁠⁠⁠    Please give us a like, share, and subscribe to stay up-to-date on future episodes! 

Brad Power spent years advising major corporations on systems design, process engineering, and decision making before lymphoma shoved him into the patient side of American healthcare. Instead of accepting the experience at face value, he started reverse engineering the machinery around cancer itself. Brad is the founder of Cancer Patient Lab and Open Cancer AI, two projects built around a blunt reality most patients discover too late: the healthcare system rewards people who know how to navigate it. Everyone else risks getting steamrolled by information asymmetry, insurance barriers, administrative friction, and institutional incentives designed around efficiency instead of human survival.The conversation starts with Harvard Business Review and Tumblr blogs before moving directly into the darker architecture underneath modern cancer care. Power explains how hospitals optimize for throughput, how insurance companies reward operational consistency over personalized medicine, and why many patients quietly end up needing a crash course in oncology, reimbursement policy, and behavioral psychology while fighting for their lives.The discussion digs into CAR-T therapy, functional testing, AI assisted decision support, and the growing collision between personalized medicine and standardized care pathways. Power argues that engaged patients often get better outcomes because they learn how to push for off guideline treatments, contest denials, and ask smarter questions. The counterpoint lands hard: patients should never have needed to become experts in the first place.The episode also explores the cultural consequences of AI entering cancer care. OpenAI advertising, data privacy, trust erosion, pharmaceutical influence, and “agentic AI” all collide inside a healthcare economy already drowning in distrust. Power sees artificial intelligence as a force multiplier for patient literacy and access. The larger system still decides who gets approved, who gets delayed, and who gets left behind.By the end, the conversation lands exactly where modern healthcare keeps forcing people to land: survival increasingly depends on learning how the machine works before the machine works on you.RELATED LINKSBrad PowerCancer Patient LabOpen Cancer AIHarvard Business ReviewResearch to the PeopleCAR T Cell TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What does it take to move a medical device from an idea to a solution that reaches patients? In this episode, Edwin Lindsay (Medtech's Guinness Guy) shares how 20+ years in medical devices shaped his hands-on approach to helping startups overcome regulatory, quality, and clinical challenges. He discusses why innovators need more than advice—they need experienced partners who help make decisions, execute strategies, and accelerate progress. Edwin also explores the hurdles facing pediatric device innovation and how his personal connection to the field inspired his mission to support founders and build stronger networks for life-changing technologies.Edwin Lindsay LinkedInCS Life Sciences WebsiteDuane Mancini LinkedInProject Medtech WebsiteProject Medtech LinkedInThank you to our sponsors: Ward Law, Wheelhouse DMG, and JumpStart Inc.

By the time the paper hit version 71, Dr. Nirosha Murugan had already done the hard part. The data were real. The experiment had worked. A team of researchers had used a wearable bioreactor to trigger limb regeneration in frogs, a result with obvious implications for regenerative medicine. But the science still wasn't getting over the line. The problem wasn't the work. It was the translation.On this episode of Standard Deviation, host Oliver Bogler talks with Dr. Nirosha Murugan, a biophysicist and Tier II Canada Research Chair in Tissue Biophysics at Wilfrid Laurier University, about what happens when a scientist working at the edges of quantum biology, bioelectricity, and tissue regeneration runs headfirst into the unwritten rules of academic publishing. Murugan's research asks biologists to think beyond molecules and chemistry alone, and to consider the physical signals, electromagnetic fields, and invisible forces that shape development and healing. It is ambitious science. It is also exactly the kind of work that can make gatekeepers nervous.Bogler follows Murugan through the less glamorous part of discovery: the hidden curriculum of getting a paper published, securing scientific credibility, and learning that data do not simply “speak for themselves.” Murugan describes how jargon buried the pitch of her own work, how a lack of editorial support left her at a disadvantage, and how the JEDI program at the Life Science Editors Foundation paired her with a former journal editor who taught her how to structure a manuscript, write a cover letter, and survive peer review.The result was publication in Science Advances, but the larger story is about power. Who gets taught the rules of biomedical research. Who has access to grant writers, editors, and institutional polish. Who is left to brute-force their way through the maze. And how one scientist, having finally found the map, now makes sure her own trainees do not have to learn it the hard way.RELATED LINKSDr. Nirosha Murugan⁠Wilfrid Laurier University⁠Life Science Editors Foundation⁠JEDI Program⁠Science Advances paper on limb regeneration⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In an AI-driven market, technology may be easier to replicate, but the right people remain a true competitive advantage. In this episode, Mike Silverstein, Managing Partner of Healthcare IT and Life Sciences at Direct Recruiters, discusses what healthcare companies often get wrong when building their teams. He explains why leaders should value grit over impressive résumés, how passive candidates can strengthen an organization, and why healthcare requires patience, resilience, and industry understanding. Mike also shares how beginning his recruiting career during the 2008 financial crisis helped him develop the relationships and determination needed to navigate future challenges. He emphasizes that lasting success comes from authenticity, meaningful networks, and consistently putting people first. Tune in to learn how healthcare organizations can build teams capable of thriving through uncertainty, technological change, and continued industry disruption. Resources Connect with Mike Silverstein on LinkedIn. Follow Direct Recruiters on LinkedIn and explore their website. Email Mike at mike@directrecruiters.com

In this episode of #CannabisUnlocked, Tiby Erdely sits down with Frederico Gomes of ATB Cormark Capital Markets to discuss why this moment in cannabis feels materially different than prior reform cycles - and why investors may finally be approaching a new institutional capital cycle.Frederico has covered the cannabis sector for more than seven years across U.S. MSOs, Canadian LPs, retailers, and ancillary operators. Having lived through the 2019 boom, a brutal bear market, and multiple federal reform false starts, he brings a seasoned perspective on what is real, what remains uncertain, and what could drive the next major leg of value creation.Fred and Tiby dive into the rapidly developing Schedule III rescheduling process, the potential timing and structure of a final rule, and why the biggest risks may be delay, litigation, and implementation - not whether cannabis ultimately moves forward. Fred explains how rescheduling could lower the cost of capital, improve cash flow, support institutional re-entry, and create a clearer path for industry leaders to emerge.The conversation then turns to valuations, uplisting, consolidation, SAFER Banking, and the rumored hemp ban. Fred discusses why many operators still trade at distressed multiples despite improving catalysts, and why exchange uplistings, cheaper capital, and limits on intoxicating hemp could drive sales growth, pricing stability, margin expansion, and renewed M&A.In closing, Tiby and Fred shift to Canada and the global cannabis opportunity, including how Canadian operators have evolved after their own boom-and-bust cycle, why Germany and international exports have become major growth drivers, and how U.S. operators may eventually participate in global markets. With rescheduling hearings underway, SAFER Banking back in the conversation, intoxicating hemp under pressure, Canadian names moving, and institutional investors beginning to revisit the sector, this episode captures one of the most important cannabis inflection points in years.Enjoy!

Life sciences are at a turning point, where scientific innovation, regulatory pressure, and patient expectations collide with unprecedented advances in data, AI, and digital platforms. IT is no longer a supporting function but a critical driver of how therapies are discovered, developed, scaled, and delivered safely and at speed.This week, Dave and Rob wrap up our State of Life Sciences mini-series with Thorsten Rall, Global Industry Lead for Life Sciences at Capgemini and together, they connect the dots across the series, exploring how AI, data and innovation are accelerating drug discovery, transforming med tech, modernising manufacturing and improving patient outcomes, all built on a strong digital foundation. TLDR00:27 – Introduction and conclusion of the Life Sciences mini-series 02:16 – Key insights and lessons from the previous episodes on the Life Sciences landscape 21:18 – Building resilient, efficient and future-ready operations 34:35 – Creating integrated, patient-centric healthcare experiences 43:15 – Why the Digital Core is the foundation for transformation and innovation 53:21 – Final reflections: the future of Life Sciences and the key takeaways 54:53 – Weekend BBQs, Thorsten's daughter's theatre performance, and the role of R&D HostsDave Chapman:  https://www.linkedin.com/in/chapmandr/Esmee van de Giessen:  https://www.linkedin.com/in/esmeevandegiessen/Rob Kernahan:  https://www.linkedin.com/in/rob-kernahan/with co-host Thorsten Rall: https://www.linkedin.com/in/thorsten-alexander-rall-b232185/ ProductionMarcel van der Burg:  https://www.linkedin.com/in/marcel-vd-burg/Dave Chapman:  https://www.linkedin.com/in/chapmandr/ SoundBen Corbett:  https://www.linkedin.com/in/ben-corbett-3b6a11135/Louis Corbett:   https://www.linkedin.com/in/louis-corbett-087250264/ 'Realities Remixed' is an original podcast from Capgemini

In medieval Europe, people who worked with early cannons and gunpowder were viewed as untrustworthy, boorish outsiders. But just a few centuries later, as they began creating elaborate fireworks displays for royalty, they went from outcasts to artists. From black powder to modern low-smoke pyrotechnics, in this episode of Tiny Matters we look at the chemistry, engineering, and artistry behind one of humanity's favorite forms of celebration. We also learn how scientists are reinventing pyrotechnics with cleaner-burning compounds that deliver brighter colors and fewer emissions. And check out this video from our friends at Headline Science to get a behind the scenes tour of the Science History Institute's new exhibit: Flash! Bang! Boom! A History of Fireworks.Check out Simple and Clean here or wherever you listen to podcasts!A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Jess Peatross trained in conventional medicine and worked as a hospitalist before she started questioning why so many chronically ill patients kept getting worse inside the healthcare system she trusted. Her perspective carries weight because she spent years following every protocol exactly as taught before walking away from hospital medicine entirely.Raised in Huntington, West Virginia during the opioid crisis, she entered medicine believing the system existed to heal people. Instead, she found hospitals driven by billing codes, liability management, and pharmaceutical dependence while patients with chronic illness, autoimmune disease, mold exposure, and chronic pain cycled endlessly through appointments and prescriptions.Dr. Peatross explains what pushed her toward functional medicine, cannabis therapy, and prevention focused care after watching patients improve only after leaving conventional treatment pipelines behind. The conversation tackles physician burnout, chronic illness stigma, healthcare incentives, and the growing collapse of trust between patients and institutions.The discussion also moves into supplements, environmental toxins, ultra processed food, and the uncomfortable economics behind keeping people permanently sick but continuously billable. Dr. Peatross describes the professional backlash that comes with challenging medical orthodoxy while Matthew connects her experience to the broader erosion of public trust across American healthcare.Together they unpack what happens when patients stop believing the system can help them and start searching elsewhere for answers.RELATED LINKSDr. Jess PeatrossInstagramMarshall UniversityBrave New WeedFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us Fan MailAbout Dr. VolkertDr. Kayla Volkert is the founder and optometrist behind See La Vie Eyecare & Eyewear, a boutique eye care practice she opened in 2022 with the goal of bringing personalized, state-of-the-art eye care to the Main Line.Originally from York, Pennsylvania, Dr. Volkert now lives in Bryn Mawr with her husband and their two young sons. She loves the walkability, charm, and strong sense of community that make the Main Line such a special place to live and raise a family—and she is proud to serve the neighborhood she calls home.Dr. Volkert earned her undergraduate degree from Penn State University, where she majored in Life Sciences and minored in French and Psychology. During college, she spent a semester studying abroad in Montpellier, France—an experience that shaped her appreciation for culture, connection, and thoughtful design.She earned her Doctor of Optometry degree from the New England College of Optometry in Boston, where she was inducted into the Beta Sigma Kappa Honor Society and received clinical honors across her rotations. While in optometry school, Dr. Volkert served as President of the Private Practice Club, reflecting her long-standing interest in improving the patient experience and building a practice rooted in personalized care. Her clinical training included advanced rotations at Bascom Palmer Eye Institute, with a focus on pediatric contact lenses, and the Baltimore VA, where she gained extensive experience in the diagnosis and management of ocular disease.After graduation, Dr. Volkert practiced optometry in Charleston, South Carolina for several years before returning to Pennsylvania to open See La Vie. Through her practice, she combines medical expertise with an elevated, boutique approach to eye care—offering comprehensive eye exams, advanced technology, and a highly personalized experience designed to help patients look, see, and feel their best.

Greg Doggett, Counsel, Powers Pyles Sutter & Verville PC, and Felicity Homsted, CEO, FQHC 340B Compliance, discuss the current legal and regulatory landscape of the 340B program. They cover the intersection of 340B with the Inflation Reduction Act, concerns about the Rebate Model, pharmaceutical manufacturer restrictions and data requirements for covered entities, AbbVie's patient definition lawsuit, state reporting requirements, and potential Congressional action.Watch this episode: https://www.youtube.com/watch?v=KsnP7hLbvekEssential Legal Updates, Now in AudioAHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Comprehensive members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast.Stay At the Forefront of Health Legal EducationLearn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/. 

Duane Mancini, Founder and CEO of Project Medtech, a Cleveland-based platform helping medical technology companies move from promising invention to real patient impact.What began as a podcast has evolved into a broader ecosystem of consulting, events, education, investor connectivity, and community-building for Medtech founders navigating the difficult path from idea to market.In our conversation, Duane and I explore his path from science and research into entrepreneurship, how Project Medtech grew from a curiosity-driven podcast into a larger platform, and what founders often underestimate about building in Medtech. We talk about regulatory strategy, reimbursement, clinical validation, fundraising, the importance of team over product, and why Ohio may have a unique opportunity to become a more important node in healthcare innovation.Duane is thoughtful, mission-driven, and deeply committed to helping more life-changing technologies reach patients. Please enjoy my conversation with Duane Mancini.00:00 Building Trust Through Storytelling07:53 The Evolution of Project MedTech12:30 The Entrepreneurial Journey Begins20:37 The Founding Team Dynamics23:43 Lessons from 250+ Conversations28:58 De-risking in Life Sciences33:38 Navigating Capital in Life Sciences38:35 Redesigning the Market Entry Process41:24 Understanding Economic Impact in Healthcare44:18 Measuring Impact and Success48:11 Optimism in Life Sciences and Med Tech50:46 Opportunities for Ohio's Life Sciences54:44 Building Supportive Ecosystems59:23 Outro-----LINKS:https://www.linkedin.com/in/duanemancinihttps://www.projectmedtech.com/-----SPONSOR:Cerity PartnersCerity Partners, a full-service investment and wealth management firm serving high-net-worth individuals, entrepreneurs, and business owners, is proud to sponsor Lay of The Land. The firm has local roots in Cleveland and across Ohio, and like this podcast, Cerity Partners advisors specialize in serving the interests of local entrepreneurs and business leaders. The firm's national presence means it can offer the resources and specialized knowledge of the largest institutions with the independence and service of a neighbor. The Cerity Partners Cleveland team understands the complexity that comes with wealth, and they adhere to fiduciary standards. Discover the financial lay of your land.Learn more at https://ceritypartners.com/NPR or call 216-464-6266.Roundstone InsuranceRoundstone Insurance is proud to sponsor Lay of The Land. Founder and CEO, Michael Schroeder, has committed full-year support for the podcast, recognizing its alignment with the company's passion for entrepreneurship, innovation, and community leadership.Headquartered in Rocky River, Ohio, Roundstone was founded in 2005 with a vision to deliver better healthcare outcomes at a more affordable cost. Over the past two decades, Roundstone has grown rapidly, creating nearly 200 jobs in Northeast Ohio. The company works closely with employers and benefits advisors to navigate the complexities of commercial health insurance and build custom plans that prioritize employee well-being over shareholder returns. By focusing on aligned incentives and better health outcomes, Roundstone is helping businesses save thousands in Per Employee Per Year healthcare costs. Roundstone Insurance — Built for entrepreneurs. Backed by innovation. Committed to Cleveland.Learn more at https://roundstoneinsurance.com/-----Stay up to date by signing up for Lay of The Land's weekly newsletter — sign up here: https://layoftheland.ck.page/5f0c1e28faConnect with Jeffrey Stern on LinkedIn — https://www.linkedin.com/in/jeffreypstern/Follow Lay of The Land on X @podlayofthelandhttps://www.jeffreys.page/

Life sciences are at a critical inflection point, where scientific innovation, regulatory demands, and patient expectations converge with advances in data and artificial intelligence, positioning IT as a central driver of faster and more effective drug discovery and clinical development.This week, Dave and Rob continue with part 3 off the Life Sciences mini-series with Predrag Angelovski, VP, CTO at Healthcare Informatics at Philips to exploring how MedTech products are more and more becoming connected platforms, combining hardware, software and services.TLDR00:21 – Introduction with co-host Thorsten Rall01:00 – Hang out: Esmee joins and Rob is lost at a train station03:00 – Dig in: Life Sciences mini-series, Part 304:57 – Conversation with Predrag Angelovski50:56 – Travelling to Europe, agents vs. agentic, and the age of intelligence GuestPredrag Angelovski: https://www.linkedin.com/in/predrag-angelovski/ HostsDave Chapman:  https://www.linkedin.com/in/chapmandr/Esmee van de Giessen:  https://www.linkedin.com/in/esmeevandegiessen/Rob Kernahan:  https://www.linkedin.com/in/rob-kernahan/ ProductionMarcel van der Burg:  https://www.linkedin.com/in/marcel-vd-burg/Dave Chapman:  https://www.linkedin.com/in/chapmandr/ SoundBen Corbett:  https://www.linkedin.com/in/ben-corbett-3b6a11135/Louis Corbett:   https://www.linkedin.com/in/louis-corbett-087250264/ 'Realities Remixed' is an original podcast from Capgemini

This week on Tiny Show and Tell Us, a listener introduces us to "FARTs" — a silly acronym for galactic gas outflows — and sends us down a rabbit hole of dying stars and recycled cosmic gas in the early universe. Then we discuss the decades-long search for broadly neutralizing antibodies (bNAbs) that can target many HIV strains at once. One bNAb that looks promising is in clinical trials right now! We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us Fan MailThe COVID-19 pandemic proved vaccine platforms can move at unprecedented speed. It also revealed how dangerously narrow the world's response really was, built almost entirely on a single technology.Dr. Dan Barouch and Kris Brown, Co-Founders of Vector Sciences, join host David E. Williams to discuss why durable pandemic preparedness depends on having multiple vaccine platforms rather than just one, how their Rheovax platform uses mucosal immunity delivered through the nose to block transmission rather than just prevent severe disease, and why public trust in vaccines depends on being honest about what each technology can and cannot actually do.

Farla Efros is a senior retail executive and former CEO who built and sold companies before facing her own breast cancer diagnosis. She brings that same operational mindset into a healthcare system that expects patients to manage complexity while they are at their most vulnerable.She was on a client call in Spain when the diagnosis came through. A clear mammogram had missed it. An MRI caught it. Within hours, she was ordering binders, building a plan, and structuring her treatment like a turnaround strategy. Every appointment became a meeting. Every doctor faced an agenda with dozens of questions. She paid out of pocket for PET scans that were denied and hired a third party firm to validate her treatment path when her own doctors resisted outside input. The conversation tracks what happens when a high-functioning executive enters a system built on delay, denial, and fragmentation. Efros describes negotiating for tests, managing physician relationships, and assembling an “executive board” of advisors across conventional and alternative care. She calls the experience “the worst client I ever had,” exposing how administrative burden shifts onto patients and families.The tension sits between what worked for her and what is inaccessible to most. Her approach requires confidence, time, and fluency in navigating power. The system rewards that behavior while quietly failing patients who cannot replicate it. Insurance coverage still left her paying out of pocket. Doctors pushed standard protocols over precision medicine. Survivorship offered little support once treatment ended.This episode examines how cancer care operates as a series of incentives rather than a coordinated system, and why patients are forced to become operators just to get through it.RELATED LINKSFarla EfrosFarla Efros on LinkedInF*ck CancerF*ck Cancer on AmazonAccentureCTOAMPULL QUOTES“I treated cancer like the worst client I ever had.”“They wouldn't approve the test, so I paid for it myself.”“Every appointment was a negotiation.”FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A custom board that ran two thousand dollars five years ago now costs fifteen and ships in two weeks. That collapse is why a hundred teenagers flew to Austin to build in the physical world instead of code in the digital. The organization behind it is Zach Latta's Hack Club, the hackathon was created by seventeen-year-old Meghana Madiraju, and Blake Liberman of 021 Ventures is why it happened in Austin. The conversation ranges from how that collapse happened to what teenagers do with the agency it hands them, and turns sharper on what threatens it. Underneath the optimism is a real question about who controls the tools of creation, code, energy, and hardware.The Agenda00:00 What Hack Club Stasis Is 06:28 How Hack Club actually works 13:01 Why hardware, why now 18:05 The case against the credential machine 24:11 Agency and the pressure myth29:33 What's actually worth building 34:38 Open source is quietly closingGuest LinksHack Club021 Ventures -------------------Austin Next Links: Website, X/Twitter, YouTube, LinkedInEcosystem Metacognition Substack

This week, Ryan Misquita of IBM shares practical Gen AI use cases in supply chain planning, from exception management and forecasting to clean data foundations, KPI measurement, and avoiding pilot purgatory.Download the ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠episode transcript⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠===== In this episode, IBM's Ryan Misquita joins us to discuss practical Gen AI in supply chain planning, real-world use cases, data governance, integration, KPI measurement, and rollout challenges. The episode also explores how AI can elevate planners and what autonomous, agentic supply chains may look like next. ===== Guest 1: Ryan Misquita, Associate Partner, IBM Consulting, IBMRyan Misquita is an Associate Partner and the IBM SCM North America Practice Leader. He has over 20 years of experience in business strategy and technology solution design across the Manufacturing, Distribution, Life Science, and Retail industries. A specialist in SAP S/4HANA, Digital Supply Chain and SAP IBP - Integrated Business Planning , Ryan has a proven track record of leading large-scale consulting engagements that transform integrated planning and manufacturing supply chain operations.Host 1: Richard Howells, SAP   ⁠⁠⁠⁠⁠⁠⁠Richard Howells⁠⁠⁠⁠⁠⁠⁠ has been working in the Supply Chain Management and Manufacturing space for over 30 years. He is responsible for driving the thought leadership and awareness of SAP's ERP, Finance, and Supply Chain solutions and is an active writer, podcaster, and thought leader on the topics of supply chain, Industry 4.0, digitization, and sustainability.===== Show Links:IBM LinkIBM IBV Report : Unified ERP for the agentic enterprise          https://www.ibm.com/thought-leadership/institute-business-value/en-us/report/unified-erp IBM IBV - The SAP advantage for generative AI https://www.ibm.com/thought-leadership/institute-business-value/en-us/report/sap-generative-aiSupply Chain Management:  ⁠⁠⁠⁠⁠⁠SAP Supply Chain Management⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠SAP Insights: Supply Chain⁠⁠⁠⁠⁠⁠       Follow Us on Social Media : Richard Howells: ⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠, SAP Digital Supply Chain: ⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠    Please give us a like, share, and subscribe to stay up-to-date on future episodes!  ===== Chapters:00:00:00: Intro00:00:59: Guest's Introductions00:02:13: Top Gen AI pain points in supply chain planning00:03:37: Practical use cases moving from pilot to production00:06:03: Building the foundation: clean data, governance, and process rigor00:07:54: AI as augmentation: elevating planners, not replacing them00:10:54: KPIs and how to measure Gen AI success00:12:40: Avoiding pilot purgatory and rollout mistakes00:17:10: How IBM supports supply chain transformation with AI00:21:50: What is the Future of Supply Chain?00:22:49: Outro

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Rachel Sha, CEO at Terrestrial Bio.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with Rachel, covering: Navigating the Genzyme Sanofi acquisition and building a leadership career on the other side of the transaction Being in the right place at the right time to pursue entrepreneurship, and the steep learning curve of stepping into a biotech CEO role The decision to adopt a dual strategy, partnering with biopharma on a platform technology while also advancing internal programs Leading a $50M Series C raise in a challenging funding environment and evolving the company's identity The real world trade offs between building manufacturing capabilities in house versus outsourcing to CDMOs Rachel Sha is the CEO at Terrestrial, a company focused on transforming the delivery of next generation therapies with its microarray skin patch that provides a patient friendly experience that is injection free and without the hassle of cold chain.  Prior to Terrestrial, she was an Operating Partner at Engine Ventures, a venture fund spun-out of MIT that invests in Tough Tech companies primarily in the Boston area.  She advised companies and worked with the investment team in exploring investment themes, opportunities, and programming.  Before her time in venture, she spent seventeen years at Genzyme and Sanofi where she held leadership positions in business development, strategy, and commercial.  Her last role at the firm was the Global Vice President of Digital Strategy, Partnering and Governance at Sanofi where she led global strategy, business development, and governance of digital programs to transform Sanofi and healthcare.   She has long been a supporter of developing women entrepreneurs and has supported organizations like Mass Next Gen and Springboard Enterprises.  She was recognized by the Boston Business Journal in the 2025 class of Women Who Lead in Life Sciences.  Rachel holds a BS from Massachusetts Institute of Technology in Chemistry and an MBA from Harvard Business School.   Please note: Vaxess Technologies is now Terrestrial (Terrestrial Bio, Inc.). This change reflects a brand evolution and is not part of a merger or acquisition. There has been no change in control or operations. All contracts, relationships and business activities continue uninterrupted under our new name.   Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

We tend to think of space as vast and mostly empty, yet the region just above Earth is far from it. In this episode, we explore the surprising congestion of low Earth orbit, where tens of thousands of satellites and millions of pieces of debris are hurtling around at incredible speeds. From a major satellite collision in 2009 to the looming threat of the Kessler Effect — where Earth's orbit becomes so densely packed that collisions set off an unstoppable chain reaction — we unpack how even tiny fragments can cause massive damage to spacecraft, disrupt critical services, and potentially put astronauts and even us Earth dwellers at risk. We talk with scientists about creative solutions that could help tackle this growing problem, including space lasers, and we ask an important question: who is responsible for keeping space clean?Check out American Medieval here or wherever you listen to podcasts!A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 2020, Emily Mendenhall drove from Washington, DC to Okoboji, Iowa, a town of 800 that swells to 200,000 every summer, and walked into a pandemic that looked nothing like the one dominating national headlines. Inside gas stations and bars, masks marked you as an outsider. In one stop, a man told her family they would not be served if they kept theirs on. Her 6 year old daughter cried, confused. Mendenhall, a medical anthropologist at Georgetown University, did what she always does. She started asking questions. Over months, she interviewed neighbors, former classmates, and local officials, including her own brother in law who helped lead the local COVID response. The result became Unmasked, a case study in how community identity, economics, and politics shaped public health decisions in real time. That work led directly into her latest book, Invisible Illness: A History, from Hysteria to Long COVID, where she tracks a much older problem. Patients with chronic illness, especially women, often fail to meet medicine's demand for proof. Without a clear diagnosis, they lose access to care, insurance coverage, and legitimacy. Mendenhall argues that long COVID did not create this failure. It exposed it.This conversation centers on how healthcare systems reward certainty and punish complexity. Long COVID clinics send patients to 17 specialists without resolution. Insurance structures require diagnoses that many conditions cannot provide. Medical training still struggles to integrate trauma, mental health, and chronic disease into a coherent model of care.Mendenhall brings lived experience into the conversation. After COVID, she dealt with months of fatigue and escalating anxiety that altered her baseline health. She does not claim the label of long COVID, but she understands how quickly the system becomes harder to navigate once symptoms stop fitting clean categories. The stakes are not theoretical. In the United States, access to healthcare, disability benefits, and treatment still depends on whether a condition can be measured, coded, and reimbursed. For millions living with invisible illness, the burden of proof becomes the illness itself.RELATED LINKSEmily MendenhallInvisible Illness: A History, from Hysteria to Long COVIDScience PoliticsGeorgetown UniversityFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

At last month's Bio-IT World Conference & Expo, Eleanor Howe, founder and CEO of Diamond Age Data Science, presented the Trends with the Trenches session based on gathered input from colleagues, clients, and advisors across the life sciences field. Coding agents were the central topic—how they're speeding up software development, open source maintenance, and analysis workflows while also shifting new types of responsibility to the human reviewer. Now, “just coding” is no longer enough, and Howe provides advice for early-career scientists on how to get hired in a different environment. Plus, she covers why simulating data can backfire, why smaller purpose-built models often win, and why better data curation, active learning, ELN automation, and federation may matter more than another flashy model demo. Links from this episode:  Bio-IT World Conference & Expo Bio-IT World BioTeam Diamond Age Data Science  Bio-IT World's Trends from the Trenches podcast delivers your insider's look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. 

We love to hear from our listeners. Send us a message.For episode 131 of Cell & Gene: The Podcast, we're sharing a recent "Better Biopharma" roundtable that Erin Harris had the opportunity to join alongside her Life Science Connect editorial colleagues. Hosted by Tyler Menichiello, this conversation brings together chief editors from across the Life Science Connect network to take a midyear look at what's shaping the pharmaceutical and biotech landscape in 2026. Featuring perspectives from Katie Anderson, Jeff Buguliskis, Ben Comer, Ray Dogum, Rachel Grabenhofer, Dan Schell, Anna Rose Welch, and Harris, this is a valuable listen for anyone looking to better understand where the industry is headed, and how CGT fits into that broader trajectory. https://www.bioprocessonline.com/solution/better-biopharmaSubscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Life sciences are at a critical inflection point, where scientific innovation, regulatory demands, and patient expectations converge with advances in data and artificial intelligence, positioning IT as a central driver of faster and more effective drug discovery and clinical development.This week, Dave and Rob continue with part 2 off the Life Sciences mini-series with Dr. Alex Zhavoronkov founder and CEO of Insilico Medicine to exploring how drug discovery and clinical development can become faster and more effective, and the role of AI in that process.  TLDR00:40 – Introduction01:00 – Hang out: Kill Bill Vol. 1 & 2 03:07 – Dig in: Life Sciences mini-series, Part 2 06:43 – Conversation with Dr Alex Zhavoronkov 42:12 – The future of AI in drug discovery and a new paradigm for pharma GuestDr. Alex Zhavoronkov: https://www.linkedin.com/in/zhavoronkov/ HostsDave Chapman:  https://www.linkedin.com/in/chapmandr/Esmee van de Giessen:  https://www.linkedin.com/in/esmeevandegiessen/Rob Kernahan:  https://www.linkedin.com/in/rob-kernahan/ ProductionMarcel van der Burg:  https://www.linkedin.com/in/marcel-vd-burg/Dave Chapman:  https://www.linkedin.com/in/chapmandr/ SoundBen Corbett:  https://www.linkedin.com/in/ben-corbett-3b6a11135/Louis Corbett:   https://www.linkedin.com/in/louis-corbett-087250264/ 'Realities Remixed' is an original podcast from Capgemini

Brett Hurt returns to Austin Next for the fourth time, more than any guest in the show's history, to argue that the hardest problem in front of us is psychological. Abundance is already on a clear technological path, and the thing most likely to stop us is the fear center we carried off the savannah. He walks through the four technologies he calls the Superfecta: AI, robotics, quantum computing, and brain-computer interfaces, and why they land together rather than in sequence. The stakes are the Great Filter and to make it through to abundance or destroy ourselves. His book lands June 23, and this conversation is the argument it rests on.Agenda0:00 Love is hard, fear is hijacked 10:21 Cooked food and broken business models 18:04 Mocktails, birth rates, and Bhutan 25:52 Moonshots and the James Webb sublime 30:42 Why aliens would be benevolent 36:13 The Superfecta changes everything 41:52 Capitalism, Chad, and abundance 51:40 Old Austin, wizards, and prophets 58:33 The nuclear math nobody wants 1:02:37 How the podcast made him hopeful 1:11:09 Open source wins the next hingeGuest Bio & LinksBrett Hurt: X, LinkedIn, Love Conquers Fear PodcastLove Conquers Fear: Humanity, AI, and the Age of Abundance for AllBrett Hurt is a serial tech entrepreneur, investor, and author. He works at the intersection of AI, leadership, and human values focusing on how society can harness exponential technologies with courage, ethics, and unity.Hurt most recently co-founded and led data-dot-world, which was acquired by ServiceNow on July 7, 2025. He previously co-founded Bazaarvoice (unicorn IPO) and Coremetrics (acquired by IBM). He also co-leads Hurt Family Investments, which is in 150 startups (12 unicorns) and 50 VC funds. He was named Austin's Best CEO (Legacy Award) and is also an Aspen Institute Henry Crown Fellow.Through his Love Conquers Fear holding company, platform, and podcast, Hurt explores how AI and emerging technologies can either amplify fear or help create broad-based human flourishing to eventually reach the Age of Abundance for All. Based in Austin, he's the author of three books and host of the Love Conquers Fear podcast, which has 60 episodes and counting. -------------------Austin Next Links: Website, X/Twitter, YouTube, LinkedInEcosystem Metacognition Substack

In this episode of Tiny Show and Tell Us, we unpack a tragic NASA accident in 1981 when technicians, preparing for the maiden voyage of Space Shuttle Columbia, were accidentally poisoned by nitrogen gas. Then guest Mischa Stanton takes us deep inside the human ear. We talk about how vibrations turn into thoughts via the cochlea and basilar membrane and dive into the fascinating world of logarithmic perception.Find Mischa at mischastanton.com.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What does responsible AI look like in practice? In this episode, we explore AI governance, AI risks, ethical AI, and how businesses can use artificial intelligence responsibly to create value without losing trust.  KEY MOMENTS    02:33 What is the current state of AI? 06:32 What are the biggest AI risks and threats? 11:00 How can AI become a force multiplier? 15:17 What is the Global AI Association? 18:00 How to connect with the guest  In this episode of the FIT4Privacy Podcast, host Punit Bhatia speaks with Pasquale Falconio from the Global AI Association about responsible AI, AI governance, generative AI, and the real business impact of artificial intelligence. They discuss where AI stands today, what makes AI risky, and how organizations can adopt AI in a way that is ethical, practical, and trustworthy.You will learn why AI itself is not the problem, why governance and human oversight matter, and how AI can support people as a super-assistant instead of replacing them. If you are interested in responsible AI, AI ethics, AI regulation, digital trust, or business transformation with AI, this conversation offers practical insights you can apply immediately.

At 25, Jace Yawnick was building a career in health and wellness sales, chasing growth, status, and the usual young adult fantasy of getting somewhere fast. Then his body stopped cooperating. Fatigue turned into chemotherapy. The diagnosis was primary mediastinal B cell non Hodgkin lymphoma, and the rest of his life split into before and after. Now in remission, he talks about cancer the way people actually live it, not the way nonprofits package it. He gets into survivorship, mental health, young adult isolation, and the deadening absurdity of prior authorization. One of the sharpest parts of the conversation lands on a simple American insult disguised as policy: treatment innovation means very little when insurance can still deny the scan, the drug, or the next step. Jace has seen that firsthand, including during routine monitoring after active treatment. This episode tracks what happens when a young cancer patient becomes a public voice and refuses to play mascot. It covers oncology, insurance, remission, advocacy, and the long mental hangover that follows survival. It also names the part too many institutions dodge: the system works great right up until it doesn't, and when it fails, patients get handed the bill, the panic, and a camera if they want anyone to care. RELATED LINKSJace Beats CancerJace Yawnick on LinkedImConquer Cancer ArticleCURE Today ArticlePyure BrandsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Microplastics are everywhere – in our water, in our food, and in our bodies. And while they are often the subject of headlines and new stories, researchers say there's still a lot to learn about how they may harm us. According to local experts, Rochester is a hot spot for the study of microplastics and health. This week, experts from across the country will be in town for a symposium exploring the latest research, challenges, and next steps for understanding how microplastics get into our environment and our bodies. Our guests preview that event and explain what we need to know about microplastics and protecting our health. In studio: Katrina Korfmacher, Ph.D., professor of environmental medicine and public health sciences at the University of Rochester and co-director of the Lake Ontario MicroPlastics Center Assemblymember Jen Lunsford, District 135 James Roussie, Ph.D., chief scientific officer and co-founder of SiMPore Christy Tyler, Ph.D., professor of environmental science in the Thomas H. Gosnell School of Life Sciences at the Rochester Institute of Technology and co-director of the Lake Ontario MicroPlastics Center ---Connections is supported by listeners like you. Head to our donation page to become a WXXI member today, support the show, and help us close the gap created by the rescission of federal funding.---Connections airs every weekday from noon-2 p.m. Join the conversation with questions or comments by phone at 1-844-295-TALK (8255) or 585-263-9994, email, Facebook or Twitter. Connections is also livestreamed on the WXXI News YouTube channel each day. You can watch live or access previous episodes here.---Do you have a story that needs to be shared? Pitch your story to Connections.

In this episode of BioTalk with Rich Bendis, Sara Dauber, Vice President, Startup Banking for J.P. Morgan's Innovation Economy team, joins the conversation to discuss how early-stage life science and healthcare companies can think more strategically about banking, financing readiness, and long-term growth.   Sara shares how her career moved from life science operating companies to NIH and now to J.P. Morgan, where she works with early-stage life science and healthcare ventures across the DMV and surrounding regions. Drawing on her experience inside startups, supporting SBIR-funded companies, and advising founders from the business side, Sara brings a practical perspective on what early-stage teams need as they begin raising institutional capital and building the systems behind a company.   The conversation explores how J.P. Morgan supports companies across the full lifecycle, from inception through IPO and beyond. Sara also discusses the importance of secure banking infrastructure, investor readiness, cap table management, startup-focused resources, and relationship-building in a market where founders are often asked to do more with limited time and capital.   Rich and Sara also revisit her time at NIH, her work with BHI Entrepreneurs-in-Residence, and the value of the BioHealth Capital Region ecosystem in helping entrepreneurs connect with the right advisors, funders, and partners.   Editing and post-production work for this episode was provided by The Podcast Consultant.   Sara Dauber is Vice President, J.P. Morgan's Startup Banking team, where she works with early-stage life science and healthcare companies in the DMV and broader Mid Atlantic. Before joining J.P. Morgan, Sara spent more than 14 years in life science operating companies, often working with early-stage startups across finance, program management, corporate development, business development, and operations. She later worked with NINDS at NIH, supporting SBIR-funded companies with business support. Today, she brings that experience to her work with founders as they build, finance, and scale life science and healthcare companies.  

On this episode, host Justin Barnes shares a conversation with Tony Nunes, Sr. Manager, Healthcare & Life Sciences, AMD from a recent AI in Action virtual summit. Their discussion focused on, From Data to Decisions: Making AI Analytics Actually Actionable. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

At 20 years old, newly arrived from Puerto Rico and trying to build a future in science, Benjamin Suarez Jimenez found himself sitting in front of two senior faculty members accused of plagiarism. He knew the material. He had done the work. His mistake came from failing to cite class notes during an exam because nobody had told him that was expected. In a matter of minutes, he watched what felt like his entire career flash before him.On this episode of Standard Deviation, host Oliver Bogler examines the hidden architecture of academic science through the experiences of Dr. Benjamin Suarez Jimenez, Assistant Professor at the University of Rochester and a neuroscientist studying PTSD, anxiety, trauma, and spatial cognition through virtual reality and video game environments.Benjamin traces his path from Puerto Rico to the mainland United States, through the NIH, Columbia University, and eventually to leading his own laboratory. Along the way, he encountered a series of barriers that had little to do with scientific ability and everything to do with access to unwritten rules. From academic gatekeeping to grant writing expectations, he learned that success in biomedical research often depends on knowledge that never appears in a textbook.Oliver explores how those invisible obstacles shape careers, influence research funding, and determine who gains access to opportunity. The conversation also examines the Justice, Equity, Diversity, and Inclusion Program at the Life Science Editors Foundation, which pairs scientists from underrepresented backgrounds with experienced scientific editors. Through that mentorship, Benjamin transformed a critical grant proposal into a successful pilot award that helped launch an NIH R01 application.The discussion extends beyond one scientist's experience. Benjamin describes helping a former mentee navigate dissertation roadblocks that threatened her graduation, illustrating how institutional bureaucracy can delay careers and discourage talented researchers. Together, they explore the hidden administrative burden, cultural barriers, and bias that many scientists carry alongside their research, and what happens when someone who receives support turns around and opens the door for others.RELATED LINKSLife Science Editors FoundationBenjamin Suarez Jimenez LabDr. Benjamin Suarez JimenezBenjamin Suarez JimenezFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Austin's counterculture is still the ethos. The next chapter is what gets built on top of it. Karen Blashek, the editor-in-chief of Austin Home Magazine, took over a 21-year-old design publication with no editorial background and turned it into one of the city's most consequential platforms for naming what's already happening. We ask why Austin's design talent operates one neighborhood away from its tech talent and neither knows the other exists. What the city is telling people and the cultural infrastructure need to make it all compound: storytellers, convening spaces, named districts, and a  patronage layer.Agenda0:00 Austin Home as civic editing4:22 Why Austin lives outside15:04 Block parties and Old Sixth21:02 Personality vs. values27:07 Ground floors as infrastructure32:10 The public space czar idea37:01 Why Austin is a design capital41:01 Naming districts that exist45:07 Three roles every ecosystem needs53:37 If you don't tell the story, someone else will58:08 The patronage gap1:03:37 Rising stars, the talent leak1:09:50 Tech and culture flywheel1:15:40 Naming what's already hereGuest Bio and LinksKaren BlashekAustin Home MagazineGroundup IdeasCities and Ambition by Paul GrahamThe City That Lingers by Ryan PuzyckiTokyo is Reinventing the Downtown by Making More Than One by Richard FloridaKaren Zabarsky Blashek is Editor-in-Chief of Austin Home Magazine, a Hearst publication covering the intersection of architecture, interiors, development, and culture in one of America's fastest-evolving cities. She is also the founder of Ground Up, a creative studio for the built environment. Before returning to her native Texas, Blashek spent 13 years in New York where she led design for Kushner, one of the country's largest real estate developers with projects nationwide. -------------------Austin Next Links: Website, X/Twitter, YouTube, LinkedInEcosystem Metacognition Substack

When Artemis II lifted off this past April, marking humanity's return to the Moon, people across the world were captivated. It was a triumph decades in the making, but also shaped by painful loss. In this episode of Tiny Matters, we trace the legacy of the Space Shuttle Challenger disaster on its 40th anniversary, unpacking what went wrong both scientifically and organizationally, and how the event necessarily helped reshape NASA's safety culture. We hear firsthand from astronaut Terry Hart, who flew on Challenger less than two years before the accident, and from NASA's acting Chief of Safety and Mission Assurance, Nathan Vassberg, about how Challenger — and later, Columbia — reshaped the way NASA thinks about risk, and how those lessons were applied to Artemis II. We also hear from Vanessa Bentley, professor of applied ethics who teaches a course dissecting the conflict between managers and engineers that led to the tragedy.Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Sarah Matt trained as a burn surgeon, working in a field where patients arrive with catastrophic injuries and survival depends on speed, skill, and resources. She left the bedside after confronting a limit that medicine does not like to admit. One physician can only see so many people in a day. The system surrounding those patients decides the rest. She moved into health technology, held leadership roles in startups, and built global infrastructure at Oracle to scale care across populations. Then she watched billions of dollars in digital health and AI initiatives stall out when they hit real clinical environments.This episode follows that pivot from surgeon to strategist and back into direct patient care in rural New York, where she now treats uninsured patients, migrant workers, and communities pushed to the margins. The conversation centers on a persistent failure across healthcare systems. Products get built for regulators, executives, and investors instead of the people who use them. The result shows up in failed adoption, broken workflows, prior authorization delays, and rising physician burnout.The discussion cuts through health policy language and lands on lived consequence. The system rewards speed over usability, scale over trust, and compliance over care. Patients absorb the fallout. Physicians carry the liability. The incentives remain intact.RELATED LINKSDr. Sarah MattThe Borderless Healthcare RevolutionThe Clinical RealistJessica FedererSovatoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Tyler Menichiello, chief editor at Bioprocess Online, host of the Better Biopharma podcast, and my Life Science Connect (LSC) colleague, convenes the broader LSC editorial team once again for a midyear discussion on what's happening now in the life sciences industry, and what's to come in the second half of the year. Topics include AI manufacturing regulations and navigating supply chain pressures, outsourcing trends and onshoring, biotech market signals and IPOs, clinical development's slow shift to digitization, the move toward organoids and non-animal models (NAMs) in discovery, RNA modality growing pains, and more.   Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Regulatory volatility, scientific‑grade context requirements, and entrenched legacy processes are creating a level of operational complexity in pharma that makes even high‑value AI initiatives difficult to move from concept to production. In this episode, Art Shectman, CEO at Elephant Ventures, examines with host Marilie Fouché how leaders can cut through that complexity by isolating a single, clearly defined workflow slice and rebuilding it for near‑term, dependable deployment rather than long‑range architectural perfection. The discussion highlights how removing outdated process assumptions, selecting an atomic workflow with organizational alignment, and aiming for a contained operational win enable pharma teams to build momentum and scale AI responsibly in highly regulated environments. Learn how consultants are winning business with evidence-based AI ROI and building long-term capabilities instead of chasing short-term gains. Download our free PDF report, "3 Keys to Thriving in the Coming Era of Automation," at emerj.com/cok1

How do you introduce AI into one of the world's most regulated industries? Dan Herron, Global VP of Digital Health at RWS, joins the Cultural Intelligence Podcast to discuss how life sciences teams can responsibly apply AI in clinical operations, COAs, and linguistic validation: * Why life sciences is uniquely complex for AI adoption, and why regulation, bias, and documentation matter so much * How AI can support faster workflows in low risk areas (green zones), while a human in the loop remains essential for patient facing and regulated content (red zones) * Why the future of linguistic validation is about responsible modernization, not automation for its own sake A conversation on AI with guardrails, the human in the loop imperative, and why the industry can't afford to wait for someone else to go first.

In the late 1980s, a child exposed to fallout from the Chernobyl disaster lay in a hospital bed while doctors told his family there were no clear answers and no reliable path forward. Decades later, that same child, Yan Leyfman, walks into exam rooms as a hematology oncology fellow, expected to deliver clarity inside a system that still runs on delay, uncertainty, and institutional self preservation.This episode traces the throughline from early life shaped by radiation exposure and hospice level uncertainty to a career inside academic medicine, translational research, and oncology media. Yan built his identity around survival and usefulness, moving from patient to physician while carrying the memory of what it feels like to sit on the other side of the table. He helped launch MedNews Week during the COVID crisis to push back on misinformation and expand access to medical knowledge, stepping into a public role while still in training.The conversation stays grounded in the friction between personal narrative and system reality. Clinical training demands efficiency, hierarchy, and emotional distance. Cancer care demands time, clarity, and human connection. Those forces collide in real patient encounters where prior authorization delays, insurance barriers, and fragmented care pathways shape outcomes as much as any treatment protocol.Yan speaks openly about mentorship, belonging, and the drive to make meaning out of survival. The discussion pushes further into what the healthcare system actually rewards, what it quietly strips away, and how quickly empathy can erode under institutional pressure. The episode also examines the role of medical media, where education, industry influence, and narrative control often blur together.This is a conversation about identity under construction, about what happens when someone who remembers powerlessness steps into a role that carries authority, and about whether that memory can survive long enough to change anything.RELATED LINKSYan Leyfman on LinkedInYan Leyfman on InstagramSurviving ChernobylFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Matthew Zachary is a brain cancer survivor, healthcare advocate, founder of Stupid Cancer and We the Patients, and host of Out of Patients. In April 2026, he returned to the stage at Merkin Hall near Lincoln Center for his first solo public piano concert in almost 22 years while launching his debut book, We the Patients: Understanding, Navigating, and Surviving America's Healthcare Nightmare.What unfolded became far larger than a concert.Over 2 hours, survivors, clinicians, advocates, nonprofit founders, journalists, pharmaceutical sponsors, and healthcare insiders gathered in one room to reflect on 30 years of survivorship, institutional failure, accidental advocacy, and the emotional afterlife of cancer. The evening moved through original piano performances, live chapter readings, and deeply personal conversations about infertility, disability, financial toxicity, insurance denials, grief, burnout, and what happens when patients spend decades navigating systems designed around transactions instead of continuity.Guests including Wendell Potter, Maimah Karmo, Craig Lustig, Shelly Fuld Nasso, Tamika Felder, and others reflected on how the modern cancer advocacy movement emerged largely because patients built parallel systems where healthcare infrastructure failed to meet human needs. The conversation explored how prior authorization, reimbursement incentives, administrative fragmentation, and institutional distrust continue shaping the patient experience across oncology and survivorship.The performance also marked a deeply personal milestone. After brain cancer compromised his left hand at age 21, Zachary spent 6 months rehabilitating both hands to return to public performance for the first time in over 2 decades. The result became part concert, part civic gathering, and part historical record of a generation of survivors who refused to disappear quietly.RELATED LINKSMZLIVE Official WebsiteMZLIVE YouTube VideoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if a single unplugged power cord nearly derailed a top biotech leader's story—and ended up launching an episode packed with innovation, real connection, and a peek inside Philadelphia's hidden biotech gems? In this lively, uplifting conversation, Lou Diamond welcomes Robert Christmas, the connector behind the Pennsylvania Biotechnology Center and the Union League's Life Science Affinity Club. They dive into the unexpected journeys that lead scientists to solve some of humanity's biggest problems, the secrets behind Philly's “pharma belt,” and the power of community-driven innovation. Along the way, you'll find out why some of the most world-changing discoveries come from people with no personal stake—and how AI, chocolate, and mountain biking fit into the life of a master connector.Get the inside edge on biotech breakthroughs, community building, and some great behind-the-scenes laughs in this episode of Thrive Loud!00:02 - Show introduction and welcome00:25 - Hilarious technical misadventure: the unplugged cord 02:09 - Robert Christmas's entry into life sciences 03:33 - Overview of the Philadelphia region's biotech significance 04:19 - How the Pennsylvania Biotechnology Center started and grew 05:51 - Types of medical breakthroughs at the center 07:59 - Spotlight: scientists who brought drugs to market 08:34 - Robert Christmas on the Union League, Philly's historic Life Science Affinity Club 10:00 - Launching a new Life Science podcast 11:28 - The power and reach of Philly's innovation ecosystem 12:37 - How the work personally impacts Robert Christmas 14:32 - Where to find, support, and connect with these organizations 17:02 - Fun speed round: movies, food, activities, and more 19:52 - AI, workflow automation, and the next generation of collaboration 22:15 - Collaborating with Jeff Gibbert and future innovation 22:51 - Closing thoughts and gratitude from Lou Diamond